IDEXX’s (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays Posted byZacks Equity Research February 8, 2022 Leave a comment on IDEXX’s (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.